Pathology: mNSCLC - L1 - PDL1 positive; non squamous - mNSCLC - L1 - Wild Type (WT); squamous - mNSCLC - L1 - all population;
| mNSCLC - L1 - PDL1 positive | non squamous - mNSCLC - L1 - Wild Type (WT) | squamous - mNSCLC - L1 - all population | ||||||
| KEYNOTE-042 (PDL1>50%), 2019 | KEYNOTE-042 (PDL1>20%), 2019 | KEYNOTE-042 (PDL1>1%), 2019 | KEYNOTE-024 (PDL1>50%), 2016 | KEYNOTE-021, 2016 | KEYNOTE-189, 2018 | KEYNOTE-407, 2018 | ||
| pembrolizumab alone | 4 | T1 | T1 | T1 | T1 | |||
| pembrolizumab plus SoC | 2 | T1 | T1 | |||||
| pembrolizumab and pemetrexed plus platin | 1 | T1 | ||||||
| placebo plus SoC | 0 | T0 | T0 | |||||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 | |||
| pemetrexed plus platin | 0 | T0 | ||||||